Medtronic has just announced a $700 million investment in Cornerstone Robotics, gaining rights to distribute its Sentire™ surgical system in selected markets outside the US. The official message is clear: Sentire is a “strong complement” to Hugo™, not a replacement. Fair enough.
But, if Hugo was the complete answer, why does Medtronic need Sentire? Hugo was Medtronic’s major bet to enter soft-tissue robotic surgery and challenge the dominance of da Vinci. Now, Medtronic is investing $700 million in another multiport robotic platform while continuing to develop Hugo.
This does not necesarilly mean that Hugo has failed. But it tells us something about the complexity of the robotic surgery market. Now, Medtronic brings global scale, commercial infrastructure and an enormous surgical technology portfolio, and Cornerstone another robotic platform, developed in Asia and already gaining regulatory traction in several markets.
The competition for market share is clearly intensifying. And once again, we end up in the same place. Hopefully, the future of surgical robotics will not belong simply to the company with the most sophisticated robot, or the coolest technology. it should belong to whoever creates the most meaningful clinical value.
J Granell. Sep 2, 2026
PS. The partnership was officially announced by Medtronic on September 1, 2026, as part of its strategy to expand its robotic-assisted surgery portfolio and offer surgeons and health systems “more choice and flexibility.”